Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.48 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5229265 | 0.92 | KCNH2 (0.51) | KCNH2EGLN2MEN1KMT2ACYP3A4 | |
| SCHEMBL5226919 | 0.90 | KCNH2 (0.51) | KCNH2CYP3A4HTTLMNAMAPT | |
| SCHEMBL5228883 | 0.90 | KCNH2 (0.53) | KCNH2MEN1KMT2ACYP3A4SMN1; SMN2 | |
| SCHEMBL508578 | 0.87 | KCNH2 (0.53) | KCNH2CYP3A4SMN1; SMN2HTTLMNA | |
| SCHEMBL5228111 | 0.87 | KCNH2 (0.53) | KCNH2CYP3A4HTTLMNAMAPT | |
| SCHEMBL5226433 | 0.86 | KCNH2 (0.51) | KCNH2CYP3A4 | |
| SCHEMBL5228148 | 0.86 | KCNH2 (0.53) | KCNH2CYP3A4SMN1; SMN2HTTLMNA | |
| SCHEMBL5226648 | 0.85 | KCNH2 (0.48) | KCNH2CYP3A4SMN1; SMN2HTTNPSR1 | |
| SCHEMBL5226693 | 0.85 | KCNH2 (0.45) | KCNH2CYP3A4 | |
| SCHEMBL5227097 | 0.85 | KCNH2 (0.52) | KCNH2MEN1KMT2ACYP3A4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1377556-B1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | PFIZER LTD (GB) | 2007-04-04 | — | — | EP | claimed |
| EP-1762567-A1 | Pyrazole derivatives for treating HIV | Pfizer Limited (GB) | 2007-03-14 | — | — | EP | claimed |
| US-20030100554-A1 | Pyrazole derivatives | JONES LYN HOWARD (GB) | 2003-05-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100554-A1 | Pyrazole derivatives | REV1, SARS1, CYP2F1 | KCNH2 3503/4885EGLN2 4029/4885MEN1 4636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.